造血干细胞支持下大剂量LACE方案对27例难治复发性淋巴瘤疗效观察

High-dose Chemotherapy with LACE and Autologous Hematopoietic Stem Cell Transplantation for Refractory and Relapsed Lymphoma

    摘要
  • 摘要: 目的:评价在造血干细胞支持下, LACE预处理方案对难治性、复发性淋巴瘤临床疗效。方法:自2001年3月至2003年7月对27例难治性、复发性淋巴瘤在造血干细胞支持下, 应用LACE预处理方案:罗氮芥(L)200mg/m2, 1次口服(移植前第7天), 足叶乙甙(E)1g/m2, 静脉点滴(移植前第7天), 阿糖胞苷(A)2g/m2×d-1, 静脉点滴(移植前第6、5天), 环磷酰胺(C)1.8/m2×d-1, 静脉点滴(移植前第4、3、2天), 0天进行自体干细胞输注并进行随访观察。结果:27例患者均可耐受化疗, 无移植相关死亡病例, 并对移植后的患者进行随访观察, 随访中位期14个月(7～35), 6例复发, 21例缓解。统计分析2年无瘤生存率可达70%, 预计5年生存率可达55%。结论:对难治性复发性淋巴瘤, 在造血干细胞支持下, LACE方案是较好的一种预处理方案。

     

    Abstract: Objective:To evaluate the outcomes of patients who received LACE (Lomustinem, Cyctoribine, Cyclophosphamide, Etoposide) conditioning regimen, following up autologous hematopoietic stem cell transplantation (ASCT) for relapsed and resistant Lymphoma. Methods: 27 Patients with relapsed and resistant Lymphoma underwent LACE conditioning regimen following-up ASCT between March 2001 and July 2003 were analyzed. Results: 9 patients with resistant lymphoma acquired tomplete remission. With14 months median follow-up the patients 2-year overall survival rate would be 70%.None patient died of transplant-related complication. Conclusion: LACE is an effective regimen for treatment of patients with relapsed and resistant lymphoma.

     

    • HTML全文
    • 参考文献(10)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回